Topics

FDA approves pegfilgrastim biosimilar Ziextenzo

05:00 EST 8 Nov 2019 | Generics and Biosimilars Initiative

Sandoz, the generics division of Novartis, announced on 5 November 2019 that it had received approval from the US Food and Drug Administration (FDA) for its pegfilgrastim biosimilar Ziextenzo (LA-EP2006).

Original Article: FDA approves pegfilgrastim biosimilar Ziextenzo

NEXT ARTICLE

More From BioPortfolio on "FDA approves pegfilgrastim biosimilar Ziextenzo"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...